Neurophet, Inc., operates as a neuroscience company, engages in the development of medical artificial intelligence solutions in the field of brain science and diseases. The company offers Neurophet AQUA, AI-powered diagnosis assistant software for brain diseases; Neurophet SCALE PET, a software that quantitatively analyzes biomarkers targeted by a specific radiotracer using PET; Neurophet tES LAB, AI-Powered software to generate a 3D model using brain MRI and simulate electrical stimulation for treatment planning; and Neurophet innk, a non-invasive electrical stimulation device designed to aid in the functional recovery and rehabilitation of patients with brain diseases. It also provides Consulting services for design systems and quality management systems. The company was founded in 2016 and is headquartered in Seoul, South Korea.
Metrics to compare | 380550 | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship Relationship380550PeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −3.0x | −0.5x | |
PEG Ratio | 0.00 | 0.18 | 0.00 | |
Price/Book | 0.0x | 2.5x | 2.6x | |
Price / LTM Sales | 0.0x | 3.4x | 3.3x | |
Upside (Analyst Target) | 0.0% | 0.0% | 43.3% | |
Fair Value Upside | Unlock | −6.2% | 6.9% | Unlock |